ArticleEClinicalMedicine2025

Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.

Abha A Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.